Etripamil + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atrial Fibrillation
Conditions
Atrial Fibrillation
Trial Timeline
Nov 19, 2020 → Aug 10, 2023
NCT ID
NCT04467905About Etripamil + Placebo
Etripamil + Placebo is a phase 2 stage product being developed by Milestone Pharmaceuticals for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT04467905. Target conditions include Atrial Fibrillation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04467905 | Phase 2 | Completed |
Competing Products
20 competing products in Atrial Fibrillation